9h25

Wesley Sundquist, University of Utah, Salt Lake City, USA
The biochemistry of HIV budding

Peter D. Kwong, Vaccine Research Center, Bethesda, USA
HIV-1 gp120, X-ray crystallography and vaccine design

Olivier Schwartz, Institut Pasteur, France
HIV, immunological and virological synapses

*Timothy Hanley, Boston University School of Medicine, Boston, USA
Nuclear receptor signalling represses HIV-1 infection of and transmission by dendritic cells

Monsef Benkirane, Human Genetic Institute, Montpellier, France
Interplay between HIV-1 replication and RNAi effectors

Thomas J. Hope, Northwestern University, Chicago, USA
Visualizing TRIM5α interactions with HIV-1 during restriction

Michael Malim, King's College, London, UK
APOBEC proteins and intrinsic resistance to HIV infection

*Julia Friedman, Case Western Reserve University, Cleveland, USA
Epigenetic shutdown of HIV transcription drives entry of HIV into latency and controls viral reactivation

Martine Peeters, IRD, Montpellier, France
Diversity of primate lentiviruses and origin of HIV

Ronald C. Desrosiers, Harvard Medical School, Southborough, USA
Alternative vaccine approaches for the prevention of HIV infection

*Rita Tendeiro, Instituto de Medicina Molecular, Lisboa, Portugal
T-cell activation in HIV-2 infected individuals: effects of viremia and ART

Françoise Barré-Sinoussi, Institut Pasteur, Paris, France
HIV/AIDS pathogenesis: to fight or to tolerate the enemy?

Anthony S. Fauci, NIAID, NIH, Bethesda, USA
A newly discovered receptor for HIV

Daniel Douek, Vaccine Research Center, Bethesda, USA
HIV disease progression: immune activation, microbes and a leaky gut

Richard A. Koup, Vaccine Research Center, Bethesda, USA
Impact of different T cell functions in the control of HIV and opportunistic pathogens

Ashley Haase, University of Minnesota, Minneapolis, USA
The critical fast stage of the slow infections lentiviruses cause

*Anna Haas, Institute of Microbiology, Zurich, Switzerland
 HIV-1 rebound affects CD4 T cell responses with specificities for persistent viral antigens

*Petronela Ancuta, University of Montreal, Montreal, Quebec, Canada
CCR6 identifies two memory CD4+ T cell subsets highly permissive to HIV infection

Dennis R. Burton, The Scripps Research Institute, La Jolla, USA
Neutralizing antibodies and an HIV vaccine

Alexandra Trkola, University Hospital Zurich, Switzerland
Fighting HIV without (yet) winning the battle: antibodies and their role in immunity to HIV

Andrew J. McMichael, Weatherall Institute of Molecular Medicine, Oxford, UK
Early events in HIV infection

Bruce D. Walker, Partners AIDS Research Center, Charleston, USA
Durable control of HIV replication

Mary Carrington, NCI, Frederick, USA
The complex influence of HLA class I and KIR on HIV-1 disease

Sunil K. Ahuja, University of Texas Health Medical Center, San Antonio, USA
From bench to bedside to populations: Translation of CCL3L1-CCR5 genetics for prevention and management of HIV-AIDS

Amalio Telenti, Institute for Microbiology, Lausanne, Switzerland
Host genomics and evolutionary genomics in HIV-1

*Nadine Gehre, University Hospital Zurich, Zurich, Switzerland
Identification of host factors critical for the host’s defence against HIV

Simon Wain-Hobson, Institut Pasteur, Paris, France
Next slide please: a vertiginous 25 years’ research

Gary Nabel, Vaccine Research Center, Bethesda, USA
AIDS vaccines at a crossroad

Brigitte Autran, Hôpital La Pitié Salpetrière, Paris, France
Therapeutic immunization against HIV: where are we now?

Pierre Charneau, Institut Pasteur, Paris, France
From HIV-1 genome nuclear import, to lentiviral vectors to a therapeutic vaccine against    AIDS

*Anders Fomsgaard, Statens Serum Institut, Copenhagen, Denmark
Dendritic cell vaccination with 7 novel subdominant HIV-1 CTL epitopes induces de novo T-cell responses

*Marie-Claire Gauduin, Southwest Foundation for Biomedical Research, San Antonio, USA
Mucosal immune responses induced by DNA/MVA and live attenuated SIV vaccine

Michel D. Kazatchkine, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
Access to treatment in the developing world: a new era

Malegapuru W. Makgoba, University of KwaZulu-Natal, KwaZulu-Natal, South Africa
27 years of responding to AIDS… the ‘picture’ onwards

Peter Hale, GTZ/German Technical Cooperation
The research outlook for the next 25 years: The big picture

Robin A. Weiss, University College, London, UK
25 years already